secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001140361-24-048293
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences releases initial Phase 1 clinical data for SENTI-202; no specific results disclosed in filing
--------------------------------------------------------------------------------

- Initial clinical data from Phase 1 trial of SENTI-202 made available in slide presentation deck.
- Data reported under Item 8.01; no specific numeric results or interim analyses provided in the 8-K body.
- Company cautions forward-looking statements; risks include clinical trial uncertainties.
- Stock ticker SNTI; filing date December 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000114036124048293/0001140361-24-048293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000114036124048293/ef20039439_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-048293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer